Stevens Capital Management LP lifted its holdings in Horizon Therapeutics PLC (NASDAQ:HZNP) by 40.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 115,086 shares of the biopharmaceutical company’s stock after buying an additional 33,204 shares during the quarter. Stevens Capital Management LP owned about 0.06% of Horizon Therapeutics worth $2,769,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in HZNP. Advisor Group Inc. grew its position in shares of Horizon Therapeutics by 18.9% in the 2nd quarter. Advisor Group Inc. now owns 9,024 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 1,432 shares during the period. Aperio Group LLC grew its position in shares of Horizon Therapeutics by 1.9% in the 2nd quarter. Aperio Group LLC now owns 36,067 shares of the biopharmaceutical company’s stock valued at $868,000 after purchasing an additional 676 shares during the period. Dupont Capital Management Corp acquired a new position in shares of Horizon Therapeutics in the 2nd quarter valued at approximately $557,000. SG Americas Securities LLC grew its position in shares of Horizon Therapeutics by 27.4% in the 2nd quarter. SG Americas Securities LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $601,000 after purchasing an additional 5,372 shares during the period. Finally, Redwood Investments LLC grew its position in shares of Horizon Therapeutics by 2.8% in the 2nd quarter. Redwood Investments LLC now owns 1,298,796 shares of the biopharmaceutical company’s stock valued at $31,249,000 after purchasing an additional 35,743 shares during the period. 87.83% of the stock is owned by institutional investors and hedge funds.
In other news, EVP Vikram Karnani sold 13,111 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $25.02, for a total transaction of $328,037.22. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jeff Kent sold 3,620 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $24.64, for a total value of $89,196.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,480 shares of company stock worth $1,230,599. Company insiders own 4.10% of the company’s stock.
NASDAQ:HZNP traded up $0.04 during trading hours on Thursday, reaching $26.66. 4,177 shares of the stock were exchanged, compared to its average volume of 1,860,394. Horizon Therapeutics PLC has a twelve month low of $16.56 and a twelve month high of $29.44. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90. The company’s 50 day simple moving average is $24.55. The stock has a market capitalization of $4.97 billion, a PE ratio of 14.58, a PEG ratio of 1.54 and a beta of 0.88.
Horizon Therapeutics (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.14. Horizon Therapeutics had a return on equity of 32.71% and a net margin of 5.90%. The firm had revenue of $320.60 million during the quarter, compared to the consensus estimate of $296.27 million. During the same quarter in the prior year, the firm posted $0.48 EPS. The business’s revenue was up 5.9% on a year-over-year basis. Analysts forecast that Horizon Therapeutics PLC will post 1.6 EPS for the current year.
Horizon Therapeutics Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Further Reading: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.